Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom

Barchart · 1d ago

More than ten countries and more than twenty sites are now participating in the Company's global pivotal trial for Huntington's disease, with over 175 patients enrolled. 

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.